2023-506700-12-00Active, not recruitingPhase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Apr 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 21 Feb 2024
- Start date
- 18 Jun 2018
- Lead sponsor
- Genentech Inc.
- Diseases
- Metastatic breast cancer
- EU CT number
- 2023-506700-12-00
- EudraCT number
- 2017-002083-41
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 45
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Active, not recruiting |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Active, not recruiting |
| Hospital Universitario HM Sanchinarro | Madrid | Spain | Active, not recruiting |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Active, not recruiting |
| MD Anderson Cancer Center | Madrid | Spain | Active, not recruiting |
| Hospital General Universitario Gregorio Marañón | Madrid | Spain | Active, not recruiting |
| Hospital Clinico Universitario de Valencia | Valencia | Spain | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.